Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial

Author(s): Ruo-Xi Hong, MD¹; Fei Xu, MD¹; Wen Xia, MD¹; Yue-E Teng, MD²; Qu-Chang Ouyang, MD³; Qiu-Fan Zheng, MD¹; Zhong-Yu Yuan, MD¹; Dong-Shao Chen, MD¹; Kui-Kui Jiang, MD¹; Ying Lin, MD⁴; Zhen Dai, MSc⁵; Xin-Lan Liu, MD⁶; Qian-Jun Chen, MD⁷; Xin-Hong Wu, MD⁸; Yan-Xia Shi, MD¹; Jia-Jia Huang, MD¹; Xin An, MD¹; Cong Xue, MD¹; Xi-Wen Bi, MD¹; Mei-Ting Chen, MD¹; Hui Li, MD⁹; He-Rui Yao, MD¹⁰; Guo-Rong Zou, MD¹¹; Heng Huang, MD¹²; Jing-Min Zhang, MD¹; Shu-Sen Wang, MD¹

Source: https://doi.org/10.1200/JCO.24.00938

Dr. Maen Hussein's Thoughts

Metronomic dose: low dose cytotoxic therapy at high frequency was studied in combination with an AI (cape at 500mg TID) and showed superiority over AI single agent, this may be an option for patients not tolerating CKD4/6 inhibitors.

PURPOSE

The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial.

METHODS

Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled. Participants were 1:1 assigned to receive either metronomic capecitabine plus an aromatase inhibitor (AI) or AI alone. The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), objective response rate, disease control rate (defined as disease controlled for ≥24 weeks), and safety.

RESULTS

A total of 263 patients were randomly assigned, among which 254 patients formed the full analysis set. At the median follow-up time of 50.7 months, 203 PFS events occurred. The metronomic capecitabine plus AI arm exhibited a median PFS of 20.9 months compared with 11.9 months in the AI arm (hazard ratio [HR], 0.58 [95% CI, 0.43 to 0.76]). The median OS was not reached in the combination arm and was 45.1 months in the AI arm (HR, 0.58 [95% CI, 0.37 to 0.93]). The most common adverse events were palmar-plantar erythrodysesthesia and peripheral neuropathy; grade 3 events occurred in 15.1% of the patients receiving combination treatment.

CONCLUSION

The MECCA trial demonstrated a significant improvement in PFS and OS with first-line metronomic capecitabine plus AI compared with AI alone in patients with hormone receptor-positive+/HER2-negative MBC. Both treatment arms exhibited tolerable safety profiles consistent with previous reports.

Author Affiliations

¹Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China;²Department of Breast Internal Medicine, The First Hospital of China Medical University, Shenyang, China;³Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China;⁴Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;⁵Chengdu Center for Disease Control and Prevention, Chengdu, China;⁶Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, China;⁷Department of Breast, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China;⁸Department of Breast Cancer, Hubei Cancer Hospital, Wuhan, China;⁹Department of Breast Surgery, Sichuan Cancer Hospital, Chengdu, China;¹⁰Breast Tumor Centre, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;¹¹Department of Oncology, Panyu District Cancer Institute, Panyu Central Hospital, Guangzhou, China;¹²Department of Breast Surgery, Lianjiang People’s Hospital, Lianjiang, China

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

The INAVO120 trial assessed inavolisib + palbociclib–fulvestrant vs placebo plus palbociclib–fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, showing significant improvements in progression-free survival (PFS) (15.0 vs 7.3 months) and overall survival (OS) (34.0 vs 27.0 months). The triplet regimen achieved a higher overall response rate (ORR) (62.7% vs 28.0%), establishing it as a potential new standard for this endocrine-resistant population. Notably, side effects like hyperglycemia, stomatitis, diarrhea, and ocular effects were more frequent with inavolisib.

Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial

The WSG-KEYRICHED-1 phase II trial evaluated a chemotherapy-free neoadjuvant regimen of pembrolizumab plus trastuzumab and pertuzumab in HER2-enriched early breast cancer, achieving a pathological complete response (pCR) rate of 46.5% (95% CI 31.2–62.6%). No survival data (e.g., EFS or OS) were reported, but the regimen showed an acceptable safety profile with no new cardiac toxicity signals. The chemo-free approach suggests promising potential for de-escalation in this subtype, but we’ll need randomized trials to confirm its efficacy and safety.

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer

In summary: It did not work in those patients with stages II-III.

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Imlunestrant (novel oral SERD) was active in patients with an ESR1 mutations, but otherwise did not offer a benefit in this population of women with ER+ HER2-neg MBC. Overall survival (OS) data is pending with further follow up.

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial

Yet another combination to consider after CDK4/6i + ET in HR+ MBC!